EnteroMedics (NASDAQ: RSLS) is one of 79 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its rivals? We will compare EnteroMedics to related companies based on the strength of its earnings, dividends, analyst recommendations, valuation, institutional ownership, risk and profitability.
This table compares EnteroMedics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
0.8% of EnteroMedics shares are held by institutional investors. Comparatively, 51.7% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 26.4% of EnteroMedics shares are held by company insiders. Comparatively, 18.2% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This is a summary of current ratings and target prices for EnteroMedics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
EnteroMedics presently has a consensus price target of $11.03, indicating a potential upside of 711.03%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 10.13%. Given EnteroMedics’ stronger consensus rating and higher probable upside, research analysts plainly believe EnteroMedics is more favorable than its rivals.
Risk and Volatility
EnteroMedics has a beta of 3, suggesting that its stock price is 200% more volatile than the S&P 500. Comparatively, EnteroMedics’ rivals have a beta of 1.25, suggesting that their average stock price is 25% more volatile than the S&P 500.
Valuation & Earnings
This table compares EnteroMedics and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|EnteroMedics Competitors||$2.18 billion||$239.60 million||-5.28|
EnteroMedics’ rivals have higher revenue and earnings than EnteroMedics. EnteroMedics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
EnteroMedics rivals beat EnteroMedics on 7 of the 12 factors compared.
EnteroMedics Company Profile
ReShape Lifesciences Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.
What are top analysts saying about EnteroMedics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for EnteroMedics Inc. and related companies.